Find Your Next Partner in Korea – and Across Asia’s Arc of Innovation

In 2026, BioCentury, BayHelix, and Insights Partner McKinsey & Company continue the debate about Asia's emerging Arc of Innovation – this time in Seoul, Korea. 

Why Korea?

Biotech's moment: From Alteogen to Ligachem to OliX and Orum, Korea biotechs are partnering with pharma and putting Korea innovation on the global map.

R&D, manufacturing: 20 years of government support has turned Korea into a global hub for clinical research and transformed Korea CDMOs like Samsung into partners of choice
for Western innovators.

NewCo ready?: Western VCs are sourcing biopharma innovation from Asia. Is Korea the next hotspot for assets and NewCo formation? 

What Will I Learn?

Highlights:

• How are Asia biotechs generating faster clinical data for their assets?
• How can I source innovation from Korea and across Asia’s Arc of Innovation?
• How can Korea de-risk Western assets via faster clinical data?
• What are the top Korea and Asia assets available for licensing and NewCos?
• Which Korea and Asia CDMOs can help accelerate my pipeline?
• Where is Korea and Asia innovation heading next on targets, modalities and indications?
• What licensing and NewCo opportunities are available in Korea, Japan, Singapore, Australia, and other emerging Asia markets?

Why Should I Attend?

The East-West Biopharma Summit is a destination event that connects Asia CEOs and investors with their peers in the West.

Network, partner and debate with:

• VCs and PEs
• Biopharma BD&L Leaders
• Biotech C-Suite
• Family Offices
• Financial Dealmakers

Meet key players from across Asia-Pacific, including:

• Australia
• China
• Japan
• India
• South Korea
• Singapore and Southeast Asia

Deliver Thought Leadership

Share your insights, elevate your brand and position yourself as a peer in BioCentury's network of biopharma decision-makers.

Learn More